Ingredion Interim Filing: Quarterly Revenue Up but Year-to-Date Profitability Slips Below Prior Year

Bottom line

- For Ingredion Inc (INGR), the 10-Q filed for period-ended-2026-06-30 and available under 0001628280-26-054722 (CIK 0001046257) presents an interim picture in which both revenue and the bottom line ran below the prior-year comparative on the six-month year-to-date view but improved on the three-month view. The earnings remain profitable on both reporting windows; the shift is one of magnitude rather than of sign. - Net Income (Loss) Attributable to Parent was $256,000,000 USD for the six-month year-to-date period the six months ended June 30, 2026, lower than the prior-year comparative of $393,000,000 USD for the six months ended June 30, 2025, and $114,000,000 USD for the three-month reporting period the three months ended June 30, 2026, higher than the prior-year comparative of $196,000,000 USD for the three months ended June 30, 2025.

The transition in both windows is profit to profit. 99 per diluted share USD/SHARES for the three months ended June 30, 2025. The transition in both windows is profit to profit.

- Operating Income (Loss) was $391,000,000 USD for the six months ended June 30, 2026, below the prior-year comparative of $547,000,000 USD for the six months ended June 30, 2025, and $188,000,000 USD for the three months ended June 30, 2026, above the prior-year comparative of $271,000,000 USD for the three months ended June 30, 2025. The transition in both windows is profit to profit. - Revenue from Contract with Customer, Excluding Assessed Tax was $3,642,000,000 USD for the six months ended June 30, 2026, lower than $3,646,000,000 USD for the six months ended June 30, 2025; and $1,850,000,000 USD for the three months ended June 30, 2026, higher than $1,833,000,000 USD for the three months ended June 30, 2025.

- The filing evidence does not attribute this change to any single cause. - The source scope for this section is the financial-statement presentation in the 10-Q filing itself; the comparative windows used are the company-reported prior-year six-month and three-month periods. No peer, industry, or third-party comparison is contained in this filing evidence, so any cross-issuer read should be drawn from a separate filing rather than from this one.

A reader who wants to compare patterns across interim filings can look at another issuer's interim write-up such as REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing, which covers a different company but a similar reporting cadence.

Financial performance

- Revenue from Contract with Customer, Excluding Assessed Tax was $1,850,000,000 USD for the three months ended June 30, 2026, compared with $1,833,000,000 USD for the three months ended June 30, 2025, a higher figure than the prior-year window. For the longer window, the same line was $3,642,000,000 USD for the six months ended June 30, 2026, against $3,646,000,000 USD for the six months ended June 30, 2025, a lower figure than the prior-year six-month period. - Operating Income (Loss) was $188,000,000 USD for the three months ended June 30, 2026, versus $271,000,000 USD for the three months ended June 30, 2025, a lower figure than the prior-year window.

The six-month window posted $391,000,000 USD for the six months ended June 30, 2026, against $547,000,000 USD for the six months ended June 30, 2025, again lower than the prior-year six-month period. - Net Income (Loss) Attributable to Parent was $114,000,000 USD for the three months ended June 30, 2026, compared with $196,000,000 USD for the three months ended June 30, 2025, a lower figure than the prior-year window. The six-month window was $256,000,000 USD for the six months ended June 30, 2026, against $393,000,000 USD for the six months ended June 30, 2025, lower than the prior-year six-month period.

99 per diluted share USD/SHARES for the three months ended June 30, 2025, a lower figure than the prior-year window. 99 per diluted share USD/SHARES for the six months ended June 30, 2025, lower than the prior-year six-month period. - In both windows the company moved from profit in the prior period to profit in the current period, so the result remained positive on the bottom line even as the headline figures slipped against the prior year.

- The filing evidence does not attribute this change to any single cause. - The filing notes several accounting items still pending assessment. Management discloses exposure to newly issued Accounting Standard Updates on expense disclosures, on hedge accounting for groups of forecasted transactions, and on environmental credits and environmental credit obligations, each with effectiveness for annual periods beginning after a year-end date and with early adoption permitted, and the company is still evaluating the impact on its Condensed Consolidated Financial Statements.

- The filing also describes a pending acquisition financed in part through a bridge facility and a delayed-draw term facility, with related derivative instruments used to hedge British pound sterling exposure, as discussed in Note 6 and Note 4. - Around the same time the company sold its majority ownership of its Pakistan business to Nishat Group while retaining a small equity interest and certain commercial arrangements, and recognized an investment in PureCircle after purchasing the remaining minority shares in an earlier quarter, as discussed in Note 2 and Note 3.

- For context, a separate interim filing shows a profit-to-profit pattern on both windows, which readers can compare against this filing at Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows. - The filing evidence contains no peer or industry comparison.

Operating drivers and segments

The filing of Ingredion Inc under 10-Q for period-ended-2026-06-30 (accession 0001628280-26-054722) reports Revenue from Contract with Customer, Excluding Assessed Tax of $1,850,000,000 for the three months ended June 30, 2026 and $3,642,000,000 for the six months ended June 30, 2026, alongside Operating Income (Loss) of $188,000,000 and $391,000,000 over the same windows. Quarter-over-quarter against the three months ended June 30, 2025, the top line is higher — the authorized direction for that comparison is an increase — while the year-to-date six-month comparison against the six months ended June 30, 2025 is an authorized decrease. Both periods remain profitable on the operating line: the quarter moves profit to profit at a lower level than $271,000,000, and the half-year window moves profit to profit at a lower level than $547,000,000. The Texture & Healthful Solutions segment is the named vehicle for share-of-results accounting — the PureCircle investment and the Agrana joint venture both flow through that segment's Other operating (income), net line. No further segment-level revenue or operating-income breakdown is captured in this section's evidence, so segment margins beyond that single naming are not derivable from the inputs. Management's narrative focuses on portfolio reshaping rather than period drivers. PureCircle was bought out in the first quarter, lifting ownership to a controlling stake, and the resulting PureCircle fair-value remeasurement is recognized in Other operating (income), net within the Texture & Healthful Solutions segment. The Pakistan business was sold to Nishat Group, with management retaining a minority equity interest and entering ongoing commercial arrangements. A pending acquisition is described as funded by a bridge facility, a delayed-draw term facility, and sterling-denominated hedging instruments documented in Note 6 and Note 4. Management also flags pending ASU adoption work covering expense disaggregation, cash-flow hedge grouping, and environmental-credit accounting, each still under assessment. The cited notes do not, on their face, attribute the period-over-period movement in revenue or operating income to any single operational driver. The filing evidence does not attribute this change to any single cause.

Independent analysis is bounded by what the catalog exposes: revenue direction differs between the quarter (higher than the prior-year quarter) and the half-year (lower than the prior-year half-year), while operating income is lower than the prior year on both windows with a profit-to-profit transition. The filing names segment mechanics for PureCircle and Agrana, but it does not quantify their contribution, so any counter-evidence on margin expansion or compression at the segment level is not available in the filing evidence. Where readers want a cross-issuer reference for an interim profit-to-profit outcome, a parallel narrative such as Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows sits outside this filing's evidence base and is offered only as adjacent context, not as a comparable. The peer-relative question — whether Ingredion's segment mix or pricing posture differs from sector peers — is not addressed by the filing evidence. The filing evidence contains no peer or industry comparison.

Cash flow and capital

[Reported facts] The six-month year-to-date period's operating cash flow was $123,000,000 USD, compared with $262,000,000 USD in the prior-year comparative six-month period. Investing activities showed a cash outflow of -$102,000,000 USD for the current six-month period, against -$203,000,000 USD in the prior-year comparative. Financing activities were a cash outflow of -$101,000,000 USD for the current six-month period and -$216,000,000 USD for the prior-year comparative. Capital expenditures on property, plant, and equipment totalled $210,000,000 USD for the current six-month period versus $193,000,000 USD in the prior-year comparative. Dividends paid were $105,000,000 USD for the current six-month period and $106,000,000 USD for the prior-year comparative. On the balance sheet at the reporting date, Cash and Cash Equivalents stood at $948,000,000 USD, Long-term Debt, Excluding Current Maturities at $1,742,000,000 USD, and Accounts Payable, Current at $651,000,000 USD.

[Authorized comparisons] Compared with the prior-year six-month period, operating cash flow was lower, while investing and financing outflows were each higher (a smaller negative); capital expenditures were higher. Dividends paid were lower than the prior-year comparative.

[Management explanations] The narrative describes derivative instruments used to hedge British pound sterling exposure on the cash consideration for the pending acquisition referenced in Note 4. It also discloses a delayed draw term loan agreement in June under which lenders committed to provide a senior unsecured delayed draw term loan facility, with initial committed borrowing availability described in the cited note and proceeds earmarked for the pending acquisition of Tate & Lyle and related refinancing, alongside the Bridge Facility referenced in Note 6. The filing evidence does not attribute this change to any single cause.

[Analyst inference] The authorized direction on operating cash flow points to softer cash generation half year over half year, while investing and financing outflows widening would be consistent with funding activity tied to the pending acquisition, including the new delayed draw term loan and hedging of the sterling-denominated consideration. The lower dividend payment gap versus the prior year is the only cash-return line that moved in a shareholder-friendly direction in the comparison window.

[Counter-evidence] Capital expenditures were higher than the prior year, which sits against any narrative that the company is pulling back on internal investment in the run-up to the pending acquisition; the higher capex run-rate is a counterweight to a pure "pre-deal pause" read.

[Unknowns] The filing does not break out free cash flow, net debt, or a full working-capital walk, and the filing evidence does not separate Tate & Lyle-related financing from any other financing inflow. The size of the DDTL and the maturity split of its tranches are described qualitatively in the cited note rather than as quantified disclosures in the cash flow statement itself.

Peer and historical context

- Top-line sequencing: Revenue from Contract with Customer, Excluding Assessed Tax in the three-month reporting window increased relative to the prior-year comparative, while the six-month year-to-date comparison shows a decrease relative to the prior-year six-month comparative — a mixed quarterly-versus-cumulative pattern that the filing evidence does not reconcile, and a contrast the cited notes Note 2, Note 3, Note 4, and Note 6 do not address. - Profitability sequencing: Operating Income (Loss) and Net Income (Loss) Attributable to Parent each decreased on both the three-month and six-month year-to-date bases versus their prior-year comparatives, and Earnings Per Share, Diluted likewise decreased on both windows; the transitions remain profit-to-profit in each case, leaving the franchise profitable on every reported window while the directional read is uniformly softer than the prior year. - Cash-flow sequencing: Net Cash Provided by (Used in) Operating Activities decreased in the six-month year-to-date window against the prior-year comparative, while financing and investing activities both shifted higher in their outflow bases against the prior year and Payments of Dividends decreased against the prior year. The cited financing notes speak to bridge and delayed-draw term loan facilities staged for the pending Tate & Lyle acquisition rather than to operating cash generation, and they do not separate ordinary-course performance from deal-related funding flows. - Capex sequencing: Payments to Acquire Property, Plant, and Equipment increased in the six-month year-to-date window against the prior-year comparative, suggesting heavier spending on long-lived assets than the prior-year six-month pace; the filing context does not tie this to any single project or category. - Peer benchmarking: The filing evidence contains no external peer or industry comparison set against Ingredion Inc (CIK 0001046257, ticker INGR) for the three months ended June 30, 2026 or the six months ended June 30, 2026, so a relative ranking versus starch-and-sweeteners peers cannot be drawn from the filing. The filing evidence contains no peer or industry comparison. - Historical pacing: The prior-year comparatives captured under the three months ended June 30, 2025 and the six months ended June 30, 2025 frame the current period against the most recent like windows only; a longer multi-year history is not contained in this filing, so secular trend claims would exceed the evidence. - Causality limit: The filing does not attribute the year-over-year shifts in revenue, operating income, net income, or operating cash flow to any single driver — for example, volume, price/mix, currency translation, input costs, or the staged Tate & Lyle transaction — and the cited notes do not supply such an attribution either. The filing evidence does not attribute this change to any single cause.

The net read is one of a still-profitable issuer reporting softer year-over-year margins and earnings alongside a higher quarterly revenue print and heavier capex, while the absence of peer data and explicit drivers keeps any broader interpretation inside the boundaries set above.

Scenario analysis

- Reported facts anchor the base case. For Ingredion Inc (INGR), the three-month reporting period shows revenue from contracts with customers of $1,850,000,000 USD and net income attributable to parent of $114,000,000 USD, while the six-month year-to-date period shows revenue of $3,642,000,000 USD and net income attributable to parent of $256,000,000 USD. - Both windows remain profitable, with year-over-year revenue directionally higher in the quarter and lower in the half-year period, and year-over-year net income directionally lower on both windows.

- Management's announced acquisition of Tate & Lyle, financed through a Bridge Facility and a delayed draw term loan arrangement described in the cited financing note, is the principal upside lever visible in the filing. - A successful close and integration would broaden the product portfolio and geographic footprint, and could lift both reported revenue and operating profitability beyond the levels captured in $1,850,000,000 USD, $3,642,000,000 USD, $114,000,000 USD and $256,000,000 USD. - Cost synergies, cross-selling into adjacent ingredient categories, and refinancing of assumed indebtedness at variable rates based on SOFR plus a margin could further support earnings expansion. - Pension and other postretirement obligations disclosed in the cited benefit note represent a recurring expense headwind; favorable movement in discount rates or asset returns would amplify upside. - Hedging programs described in the cited derivative note, along with marketable securities, commodity and foreign currency forwards, futures, options and swap contracts recognized at fair value using Level 1, Level 2 and Level 3 inputs, could also reduce volatility of input costs.

- A decline in the reported figures remains the dominant downside. Revenue directionally fell in the half-year period versus $3,646,000,000 USD, and net income fell on both windows versus $196,000,000 USD and $393,000,000 USD. - If the Tate & Lyle transaction does not close or integration falters, transaction-related costs already absorbed plus committed financing capacity would weigh on margins without offsetting revenue contribution. - Higher SOFR-linked borrowing costs on the Bridge Facility and delayed draw term loan, combined with refinancing of acquired indebtedness, could pressure interest expense and net income below $114,000,000 USD and $256,000,000 USD. - Adverse fair-value movements on Level 3 instruments, weaker commodity hedging outcomes, or unfavorable shifts in pension assumptions could amplify the downside. - Share repurchase activity noted in the cited authorization could be curtailed if liquidity tightens, removing a per-share support mechanism. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. - The filing evidence does not disclose segment-level detail for this dimension. Readers weighing scenario probabilities may compare this profile with the parallel profit-to-profit trajectory observed in REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in period-ended-2026-06-30 Filing to gauge how similar headline moves have resolved elsewhere.

Risks and what to watch

- Reported facts versus management framing: For the six-month year-to-date period, Net Income (Loss) Attributable to Parent is reported at $256,000,000 against a prior-year comparative of $393,000,000, with the authorized direction a decrease and both periods remaining in profit. Revenue from Contract with Customer, Excluding Assessed Tax for the same window is reported at $3,642,000,000 against a prior-year comparative of $3,646,000,000, also an authorized decrease. For the three-month reporting period, Net Income (Loss) Attributable to Parent is reported at $114,000,000 against a prior-year comparative of $196,000,000 (authorized decrease, profit-to-profit), while Revenue from Contract with Customer, Excluding Assessed Tax is reported at $1,850,000,000 against a prior-year comparative of $1,833,000,000, which the evidence authorizes as higher on a year-over-year basis.

The cross-window picture shows revenue up quarter-on-quarter but down year-to-date alongside a profit decline on both windows, which is a tension that management in the cited Item 2 discussion does not reconcile line-by-line. - Counter-evidence and what the narrative does not support: The borrowed-proceeds discussion around the Bridge Facility and the delayed draw term loan arrangement, captured in the cited notes including Note 6 and the Bridge and DDTL disclosures, frames the financing as purpose-built for the pending Tate & Lyle transaction, yet the filing does not quantify any synergy, integration cost or accretion figure that could be tested against the year-to-date profit decline.

- Unknowns and disclosure gaps: Causality for the half-year revenue and earnings slip versus the year-ago period is not attributed to any single driver by management; that statement is recorded here as The filing evidence does not attribute this change to any single cause.. Segment-level colour for the quarter is not separately broken out, so any read-through to Food Ingredients, Sweetening Solutions, or the erstwhile replacement line is recorded as The filing evidence does not disclose segment-level detail for this dimension..

No external peer benchmark appears in the filing, so any inference about Ingredion's relative performance is recorded as The filing evidence contains no peer or industry comparison.. - Risks carried forward into the next window: Exposure sits in fair-value classification of acquisition-related derivatives tied to the Tate & Lyle consideration, referenced via the lower fair-value tiers in Level 1, Level 2 and the unobservable inputs tier in Level 3; in hedge-accounting costs disclosed in Note 4; and in the pure-circle-related investment treatment in Note 3.

Contingent legal, regulatory and tax items appear under Item 1 and Item 4, including the controls discussion carried into Item 3, and exhibit-level mechanics referenced under Item 5 and Item 6. - Metrics to watch next period: Continuous readers can keep an eye on another interim filing alongside this one, such as the UFP TECHNOLOGIES INC Interim Filing Profit-to-Profit Growth piece, although for headline numbers the four revenue and net income points above plus the operating-cash direction and capex direction referenced in the statement of cash flows are the four cleanest read-throughs into the next period.